The U.S. Food and Drug Administration will continue to monitor the recently approved Zohydro ER, an extended-release opioid, as it works with law enforcement to help ensure appropriate use of the drug and with the manufacturer to develop a "meaningful" abuse-deterrent formulation, FDA Commissioner Dr. Margaret A. Hamburg told attendees at a conference April 22. Speaking at the 201... Read More